<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01253681</url>
  </required_header>
  <id_info>
    <org_study_id>20090155</org_study_id>
    <nct_id>NCT01253681</nct_id>
  </id_info>
  <brief_title>Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer</brief_title>
  <official_title>A Phase 1b Open-Label, Multi-Center Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With High-Risk Stage I and Stages II-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate whether AMG 386 in combination with paclitaxel and carboplatin is safe and well
      tolerated in the first-line treatment of high-risk stage I and stages II-IV epithelial
      ovarian, primary peritoneal and fallopian tube cancers. The hypothesis is that AMG 386 in
      combination with carboplatin and paclitaxel is safe and well tolerated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate whether AMG 386 in combination with paclitaxel and carboplatin is safe and well
      tolerated in the first-line treatment of high-risk stage I and stages II-IV epithelial
      ovarian, primary peritoneal and fallopian tube cancers. The hypothesis is that AMG 386 in
      combination with carboplatin and paclitaxel is safe and well tolerated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate whether AMG 386 in combination with paclitaxel and carboplatin is safe and well tolerated in the first-line treatment of high-risk stage I and stages II-IV epithelial ovarian, primary peritoneal and fallopian tube cancers.</measure>
    <time_frame>18 weeks of combination therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the pharmacokinetics (Cmax, AUC and Cmin) of AMG 386 in combination with carboplatin and paclitaxel</measure>
    <time_frame>Week 1 until Week 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate the incidence of anti-AMG 386 antibody formation</measure>
    <time_frame>Week 1 until maximum of 1 year following first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the objective response rate (ORR) among subjects receiving AMG 386 in combination with carboplatin and paclitaxel</measure>
    <time_frame>From date of first dose until the subject reaches End of Study. This will continue until 36 months after the last subject has been enrolled.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the duration of response (DOR) among subjects receiving AMG 386 in combination with carboplatin and paclitaxel</measure>
    <time_frame>From date of first dose until the subject reaches End of Study. This will continue until 36 months after the last subject has been enrolled.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate progression-free survival (PFS) among subjects receiving AMG 386 in combination with carboplatin and paclitaxel</measure>
    <time_frame>From date of first dose until the subject reaches End of Study. This will continue until 36 months after the last subject has been enrolled.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the number of participants with adverse events and clinical laboratory abnormalities</measure>
    <time_frame>96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of AMG 386 on the pharmacokinetics (Cmax, AUC and Cmin) of carboplatin and paclitaxel</measure>
    <time_frame>Week 1 until Week 7</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Carcinoma</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Primary Peritoneal Cancer</condition>
  <arm_group>
    <arm_group_label>AMG 386, paclitaxel and carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mg/Kg AMG 386 IV (intravenous) weekly plus paclitaxel and carboplatin IV Q3W for 18 weeks, followed by 15mg/Kg AMG 386 IV (intravenous) weekly alone for an additional 18 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 386, paclitaxel and carboplatin</intervention_name>
    <description>15 mg/Kg AMG 386 IV (intravenous) weekly plus paclitaxel and carboplatin IV Q3W for 18 weeks, followed by 15mg/Kg AMG 386 IV (intravenous) weekly alone for an additional 18 months.</description>
    <arm_group_label>AMG 386, paclitaxel and carboplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female subjects more than 18 years of age with newly diagnosed high-risk FIGO Stage I
             (grade 3, or aneuploid grade 1 or 2) or Stages II-IV epithelial ovarian, primary
             peritoneal and fallopian tube cancer with an indication for first-line treatment with
             paclitaxel and carboplatin x 6 cycles. Subjects with pseudomyxoma, mesothelioma,
             adenocarcinoma of unknown primary tumor, sarcoma, or neuroendocrine histology are
             excluded.

          -  Subjects with high-risk stage I, stage II, or stage IIIA-B must have had prior primary
             debulking surgery that occurred no less than 4 weeks, and no more than 12 weeks, prior
             to enrollment. Subjects must have recovered fully from surgery in the opinion of the
             investigator

          -  Subjects with Stage IIIC or IV disease who have not had primary debulking surgery must
             have planned interval debulking surgery following 3 cycles of AMG 386, paclitaxel and
             carboplatin

          -  Female 18 years of age or older at the time the written informed consent is obtained

          -  Subjects of child-bearing potential who have not undergone a bilateral
             salpingo-oophorectomy and are sexually active must consent to use an accepted and
             effective non-hormonal method of contraception (i.e, double barrier method (eg, condom
             plus diaphragm) from signing the informed consent through 6 months after last dose of
             study drug

          -  GOG Performance Status of 0 or 1

          -  Life expectancy ≥ 3 months (per investigator opinion)

          -  Subject plans to begin protocol-directed therapy within 7 days from enrollment

          -  Adequate organ and hematological function as evidenced by the following laboratory
             studies prior to enrollment:

        Hematological function, as follows:

          -  Hemoglobin ≥ 9 g/dL

          -  Absolute neutrophil count (ANC) ≥ 1.5 x 10x9/L

          -  Platelet count ≥ 100 x 10x9/L and ≤ 850 x 10x9/L

          -  PTT or aPTT ≤ 1.5 x ULN per institutional laboratory range and INR ≤ 1.5

        Renal function, as follows:

          -  Urinary protein quantitative value of ≤ 30 mg/dL in urinalysis or ≤ 1+ on dipstick,
             unless quantitative protein is &lt; 1000 mg in a 24 hour urine sample

          -  Creatinine clearance &gt; 40 mL/min per 24-hr urine collection or calculated according to
             the Cockcroft-Gault formula

        Hepatic function, as follows:

          -  AST and ALT ≤ 2.5 x ULN per institutional laboratory range (or ≤ 5 x ULN if liver
             metastases are present)

          -  Total bilirubin ≤ 1.5x institutions' ULN Nutritional

          -  Albumin ≥ 2.8 g/dL

        Exclusion Criteria:

          -  Prior use of anticancer therapy or experimental therapy for epithelial ovarian,
             primary peritoneal or fallopian tube cancers

          -  Previous abdominal and/or pelvic external beam radiotherapy

          -  Subjects believed to be a higher than average risk of bowel perforation. This includes
             current symptoms of partial or complete bowel obstruction, recent (within 6 months)
             history of fistula or bowel perforation, subjects requiring total parenteral nutrition
             and continuous hydration

          -  History of arterial or venous thromboembolism within 12 months prior to enrollment

          -  History of clinically significant bleeding within 6 months prior to enrollment

          -  History of central nervous system metastasis

          -  Known active or ongoing infection (except uncomplicated urinary tract infection)
             within 14 days prior to enrollment

          -  Currently or previously treated with AMG 386, or other molecules that inhibit the
             angiopoietins or Tie2 receptor

          -  Current or within 30 days prior to enrollment treatment with immune modulators such as
             systemic cyclosporine or tacrolimus

          -  Prior myeloablative high-dose chemotherapy with allogeneic or autologous stem cell (or
             bone marrow) transplant

          -  Clinically significant cardiac disease within 12 months prior to enrollment, including
             myocardial infarction, unstable angina, grade 2 or greater peripheral vascular
             disease, cerebrovascular accident, transient ischemic attack, congestive heart
             failure, or arrhythmias not controlled by outpatient medication or placement of
             percutaneous transluminal coronary angioplasty/stent

          -  Uncontrolled hypertension as defined as diastolic blood pressure &gt; 90 mmHg OR systolic
             blood pressure &gt; 140 mmHg. The use of anti-hypertensive medications to control
             hypertension is permitted

          -  Subjects with a history of prior malignancy, except:

        Malignancy treated with curative intent and with no known active disease present for ≥ 3
        years prior to enrollment and felt to be at low risk for recurrence by treating physician,
        Adequately treated non-melanomatous skin cancer or lentigo maligna without evidence of
        disease Adequately treated cervical carcinoma in situ without evidence of disease

          -  Major surgery within 28 days prior to enrollment or still recovering from prior
             surgery

          -  Minor surgical procedures, including placement of tunneled central venous access
             device, within 3 days prior to enrollment

          -  History of allergic reactions to bacterially-produced proteins

          -  Hypersensitivity to paclitaxel or drugs using the vehicle cremophor

          -  Pregnant (ie, positive beta-human chorionic gonadotropin test) or is breast feeding or
             planning to become pregnant within 6 months after the end of treatment

          -  Subject has known positive test(s) for human immunodeficiency virus (HIV) infection,
             hepatitis C virus, acute or chronic active hepatitis B infection

          -  Any condition which in the investigator's opinion makes the subject unsuitable for
             study participation

          -  Any uncontrolled concurrent illness or history of any medical condition that may
             interfere with the interpretation of the study results

          -  Non-healing wound, ulcer (including gastrointestinal) or fracture

          -  Subject has previously been enrolled onto this study

          -  Subject will not be available for follow-up assessment

          -  Subject has known sensitivity to any of the products to be administered during dosing

          -  Subject has any kind of disorder that compromises the ability of the subject to give
             written informed consent and/or to comply with study procedures
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Footscray</city>
        <state>Victoria</state>
        <zip>3011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Malvern</city>
        <state>Victoria</state>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2010</study_first_submitted>
  <study_first_submitted_qc>December 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2010</study_first_posted>
  <last_update_submitted>October 13, 2015</last_update_submitted>
  <last_update_submitted_qc>October 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AMG 386</keyword>
  <keyword>Ovarian Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Trebananib</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

